Literature DB >> 25944189

Novel lymphocyte screening tube using dried monoclonal antibody reagents.

Benjamin D Hedley1, Michael Keeney1, Janice Popma1, Ian Chin-Yee2.   

Abstract

We previously developed a 10-color 11-antibody combination including a viability dye, to screen T-, B-, and natural killer (NK)-cell populations in blood, bone marrow, tissue, and body fluids. Recently, Beckman Coulter has introduced a line of dried reagents that, unlike liquid reagents and cocktails, require no refrigeration, titration, or manipulation before using. We evaluated custom tubes based on our standard lymphocyte screening panel, focusing on comparative analysis, ease of use, and advantages compared with our liquid reagent set. We tested 42 samples from blood (n = 15), bone marrow (n = 17), and tissue (n = 10) with the combination CD4/CD8/KAPPA/LAMBDA/CD19/CD56/CD5/CD20/CD10/CD3/CD45 and a vital dye by both methods and compared positivity and staining intensity for each antigen. Of the 42 samples, 5 were normal samples, 3 were red cell disorders, 20 were B-cell malignancies, 5 T-cell malignancies, 4 myeloid malignancies, and the remaining 5 were other diagnoses. Dried reagents gave equivalent staining intensity results to our standard panel in a variety of sample types, with diagnoses including reactive lymphocytosis, chronic lymphocytic leukemia, and various lymphomas. Our standard panel for evaluation of mature lymphoid malignancies allows rapid assessment of any sample type while providing direct assessment of viability. The dried reagent tube reduces preanalytical work, with simple addition of sample and the viability dye to the tube, saving time, reducing potential errors, and obviating need to titrate and monitor individual antibodies. With a shelf life of at least 12 months, the reagents also offer potential savings in reagent costs by reducing wastage due to expiration or tandem breakdown in standard liquid formulation.
© 2015 International Clinical Cytometry Society.

Entities:  

Keywords:  acute leukemia; duraclone; flow cytometry; immunophenotyping; screening tube

Mesh:

Substances:

Year:  2015        PMID: 25944189     DOI: 10.1002/cyto.b.21251

Source DB:  PubMed          Journal:  Cytometry B Clin Cytom        ISSN: 1552-4949            Impact factor:   3.058


  7 in total

1.  A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies.

Authors:  Sabine Ivison; Mehrnoush Malek; Rosa V Garcia; Raewyn Broady; Anne Halpin; Manon Richaud; Rollin F Brant; Szu-I Wang; Mathieu Goupil; Qingdong Guan; Peter Ashton; Jason Warren; Amr Rajab; Simon Urschel; Deepali Kumar; Mathias Streitz; Birgit Sawitzki; Stephan Schlickeiser; Janetta J Bijl; Donna A Wall; Jean-Sebastien Delisle; Lori J West; Ryan R Brinkman; Megan K Levings
Journal:  JCI Insight       Date:  2018-12-06

2.  OMIP - 081: A new 21-monoclonal antibody 10-color panel for diagnostic polychromatic immunophenotyping.

Authors:  Erik H L P G Huys; Willemijn Hobo; Frank W M B Preijers
Journal:  Cytometry A       Date:  2021-11-01       Impact factor: 4.714

3.  Standardization procedure for flow cytometry data harmonization in prospective multicenter studies.

Authors:  Lucas Le Lann; Pierre-Emmanuel Jouve; Marta Alarcón-Riquelme; Christophe Jamin; Jacques-Olivier Pers
Journal:  Sci Rep       Date:  2020-07-14       Impact factor: 4.379

4.  A multicenter study evaluation of the ClearLLab 10C panels.

Authors:  Benjamin D Hedley; Guoyan Cheng; Michael Keeney; Wolfgang Kern; Adrian Padurean; Joanne Luider; Ian Chin-Yee; Lori E Lowes; Justin Rohrbach; Robert Ortega; Astrid Smit; Ka-Wai Lo; Robert Magari; Liliana Tejidor
Journal:  Cytometry B Clin Cytom       Date:  2020-07-15       Impact factor: 3.058

5.  Evaluation of fixed-panel, multicolour ClearLLab 10C at an academic flow cytometry laboratory in Johannesburg, South Africa.

Authors:  Deborah K Glencross; Leanne Swart; Melanie Pretorius; Denise Lawrie
Journal:  Afr J Lab Med       Date:  2022-07-15

6.  Changes in peripheral immune cells after intraoperative radiation therapy in low-risk breast cancer.

Authors:  Isabel Linares-Galiana; Miguel Angel Berenguer-Frances; Rut Cañas-Cortés; Monica Pujol-Canadell; Silvia Comas-Antón; Evelyn Martínez; Maria Laplana; Héctor Pérez-Montero; María Jesús Pla-Farnós; Arturo Navarro-Martin; Miriam Nuñez; Brigitte Both; Ferran Guedea
Journal:  J Radiat Res       Date:  2021-01-01       Impact factor: 2.724

7.  Aberrant expression of CD54 detected by flow cytometry is a characteristic of B-lymphoma cells in bone marrow specimens.

Authors:  Wei Wang; Yan Li; Haval Ali; Linjun Zhao; Di Mei; Wenqing Hu; Bin Jiang
Journal:  BMC Cancer       Date:  2021-12-08       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.